Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Goldstein LJ, Mansutti M, Levy C, Chang JC, Henry S, Fernandez-Perez I, Prausovà J, Staroslawska E, Viale G, Butler B, McCanna S, Ruffini PA, Wicha MS, Schott AF; fRida Trial Investigators. Goldstein LJ, et al. Breast Cancer Res Treat. 2021 Nov;190(2):265-275. doi: 10.1007/s10549-021-06367-5. Epub 2021 Sep 3. Breast Cancer Res Treat. 2021. PMID: 34476645 Free PMC article. Clinical Trial.
Medical management of early-stage breast cancer.
Bookman MA, Goldstein LJ, Scher RM. Bookman MA, et al. Among authors: goldstein lj. Curr Probl Cancer. 1991 Jul-Aug;15(4):157-232. doi: 10.1016/0147-0272(91)90020-b. Curr Probl Cancer. 1991. PMID: 1874006 Review.
Operable breast cancer.
Cianfrocca M, Goldstein LJ. Cianfrocca M, et al. Among authors: goldstein lj. Curr Treat Options Oncol. 2001 Apr;2(2):157-67. doi: 10.1007/s11864-001-0058-9. Curr Treat Options Oncol. 2001. PMID: 12057134 Review.
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Goldstein LJ, et al. J Clin Oncol. 2008 Sep 1;26(25):4092-9. doi: 10.1200/JCO.2008.16.7841. Epub 2008 Aug 4. J Clin Oncol. 2008. PMID: 18678836 Free PMC article. Clinical Trial.
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Solin LJ, et al. Among authors: goldstein lj. Breast Cancer Res Treat. 2012 Jul;134(2):683-92. doi: 10.1007/s10549-012-2072-y. Epub 2012 May 1. Breast Cancer Res Treat. 2012. PMID: 22547108 Free PMC article.
211 results